GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » YoY EBITDA Growth

Belite Bio (Belite Bio) YoY EBITDA Growth : 14.33% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Belite Bio's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 14.33%.

Belite Bio's EBITDA per Share for the three months ended in Mar. 2024 was $-0.28.

Belite Bio YoY EBITDA Growth Historical Data

The historical data trend for Belite Bio's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio YoY EBITDA Growth Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- -68.78 -55.50 -88.59

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -645.45 -109.45 -293.14 7.25 14.33

Belite Bio YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Belite Bio's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1.173--0.622)/ | -0.622 |
=-88.59 %

Belite Bio's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.281--0.328)/ | -0.328 |
=14.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Belite Bio's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » YoY EBITDA Growth
Comparable Companies
RXRX MNKD KNSA BCRX XNCR MIRM EQRX IRON VIR CLDX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
D01:Germany
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Website
https://www.belitebio.com
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.